| [1] |
《蕈样肉芽肿治疗中国专家共识(2023)》编写专家组, 沈小雁, 郑捷. 蕈样肉芽肿治疗中国专家共识(2023)[J].中华皮肤科杂志,2023,56(5): 402-409. DOI:10.35541/cjd.20220909. |
| [2] |
Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome-update 2023[J].Eur J Cancer,2023,195: 113343. DOI:10.1016/j.ejca.2023.113343. |
| [3] |
Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J].Lancet,2017,390(10094): 555-566. DOI:10.1016/S0140-6736(17)31266-7. pmid:28600132 |
| [4] |
Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis[J].Eur J Cancer,2021,148: 411-421. DOI:10.1016/j.ejca.2021.01.054. pmid:33794441 |
| [5] |
国家癌症中心/国家肿瘤质控中心. 蕈样霉菌病全身皮肤放射治疗临床指南[J].中华放射肿瘤学杂志,2024,33(8): 687-697. DOI:10.3760/cma.j.cn113030-20230602-00154. |
| [6] |
中国临床肿瘤学会(CSCO)淋巴瘤专家委员会. 常见原发性皮肤T细胞淋巴瘤诊疗中国专家共识(2024年版)[J].白血病·淋巴瘤,2024,33(6): 321-328. DOI:10.3760/cma.j.cn115356-20240520-00067. |
| [7] |
Photiou L, van der Weyden C, McCormack C, et al. Systemic treatment options for advanced-stage mycosis fungoides and Sézary syndrome[J].Curr Oncol Rep,2018,20(4): 32. DOI:10.1007/s11912-018-0678-x. |
| [8] |
Ribereau-Gayon E, Donzel M, Pham F, et al. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas[J].Leuk Lymphoma,2023,64(8): 1424-1432. DOI:10.1080/10428194.2023.2216820. |
| [9] |
Torre‐Castro J, Recio‐Monescillo M, Castillo Bazan E, et al. Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides[J].Int J Dermatol,2024,63(6): 828-830. DOI:10.1111/ijd.17107. |
| [10] |
Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J].Ann Oncol,2015,26(8): 1766-1771. DOI:10.1093/annonc/mdv237. pmid:26105599 |
| [11] |
Zhang N, Zhang S, Ma L, et al. Case report: successful treatment of chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT[J].Medicine (Baltimore),2023,102(40): e35413. DOI:10.1097/MD.0000000000035413. |
| [12] |
魏冲, 张炎, 张薇, 等. 西达本胺联合PD-1单抗治疗Sézary综合征获得持续缓解1例[J].中华血液学杂志,2022,43(2): 165. DOI:10.3760/cma.j.issn.0253-2727.2022.02.016. |